BeStock  
Stocks › Biotechnology › SVRA

Savara SVRA

US equityMarket cap rank #3240Biotechnology
$4.88 +$0.23 (+4.95%)
Pre-market · Oct 8, 9:10 am ET · After hours $4.98 +1.95%
Open$4.74
Prev close$4.65
Day range$4.69 – $5.05
Volume2.42M
Market cap$1.00B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership86.0%-0.06 pts vs. prior quarter
Institutions holding203-1 vs. prior quarter
Insider trades (recent)23 buys / 23 sellsBalanced
Short interest21.10% of floatDays to cover 36.3 · as of 15 Sep 2026
Short-sale volume share20.2%5-day average of daily volume

Short-sale volume as % of daily volume

11%16%22%27%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$13.54M (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

−$14.7MSuper+$1.1MBig+$365.2KMid+$39.4KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 32.6% of shares outstanding.

Largest holders

  • New Enterprise Associates, Inc.9.63%
  • Bain Capital Life Sciences Investors, LLC6.93%
  • VR Management, LLC5.80%
  • Deerfield Management Company, L.P.5.34%
  • BlackRock4.92%
  • TCG Crossover Management, LLC4.86%
  • Frazier Life Sciences Management, LP3.83%
  • Polar Capital Holdings Plc3.75%

By investor type

  • VC/PE Fund33.88%
  • Mutual Fund26.91%
  • Hedge Fund23.65%
  • Individual/Insider2.10%
  • Public Company0.78%
  • Private Company0.41%
  • Government Pension Fund0.14%
  • Insurance Company0.12%

Reported short interest has risen from 15.63% to 21.10% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Nuveen Asset Management LLC Insurance Company 2026/Q3 +203,505 0.1%
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +3,324,900 1.6%
Marshall Wace LLP Hedge Fund 2026/Q3 +1,742,641 2.5%
BlackRock Mutual Fund 2026/Q3 +1,203,313 4.9%
VR Management, LLC VC/PE Fund 2026/Q3 +1,005,568 5.8%
Pictet Asset Management Limited Mutual Fund 2026/Q3 +487,674 1.1%
Algert Global LLC Hedge Fund 2026/Q3 +464,645 0.5%
Janus Henderson Group plc Mutual Fund 2026/Q3 +421,411 0.2%
Y-Intercept (Hong Kong) Limited Mutual Fund 2026/Q3 +410,609 0.2%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q3 +403,116 1.0%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +277,653 1.5%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +260,361 0.6%
GuideStone Capital Management, LLC Mutual Fund 2026/Q3 +209,095 0.1%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +184,891 3.5%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +167,192 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
23 Sep 2026 Braden Parker Chief Commercial Officer Sale to Issuer -29,323 $5.07 55,677
14 Jul 2026 Robert Lutz Chief Operating Officer Other Acquisition +35,000 – 135,000
14 Jul 2026 Robert Lutz Chief Operating Officer Other Derivative Acquisition +70,000 $5.81 70,000
21 Jun 2026 David Lowrance CFO, Chief Administrative Officer & Secretary Derivative Exercise and Sale -580,187 $5.68 436,032
17 Mar 2026 David Lowrance CFO, Chief Administrative Officer & Secretary Derivative Exercise and Sale -116,760 $5.04 436,032
17 Mar 2026 David Lowrance CFO, Chief Administrative Officer & Secretary Derivative Exercise and Retained +249,987 $4.45 436,032
15 Feb 2026 Joseph S. McCracken Lead Independent Director Derivative Exercise and Retained +1,807 $1.76 262,644
18 Dec 2025 David Ramsay Independent Director Open Market Disposition -20,000 $6.06 2,493,642
17 Dec 2025 David Ramsay Independent Director Intent to Sell (Form 144) -20,000 $6.11 –
15 Dec 2025 David Lowrance CFO, Chief Administrative Officer & Secretary Other Disposition -32,000 – 186,045
15 Dec 2025 Matthew Pauls Chairperson & CEO Other Disposition -128,995 – 788,050
13 Dec 2025 David Lowrance CFO, Chief Administrative Officer & Secretary Sale to Issuer -62,960 $6.92 186,045
13 Dec 2025 Matthew Pauls Chairperson & CEO Sale to Issuer -195,705 $6.92 788,050
13 Dec 2025 Robert Lutz Chief Operating Officer Sale to Issuer -67,760 $6.92 193,977
13 Dec 2025 Anne Erickson Chief Business Officer Sale to Issuer -62,960 $6.92 271,712
13 Dec 2025 Kate McCabe General Counsel Sale to Issuer -39,350 $6.92 519,232
9 Dec 2025 Matthew Pauls Chairperson & CEO Other Disposition -23,629 – 662,750
8 Dec 2025 David Ramsay Independent Director Other Acquisition +40,000 – 80,000
8 Dec 2025 Joseph S. McCracken Lead Independent Director Other Acquisition +40,000 – 80,000
8 Dec 2025 Richard Hawkins Independent Director Other Acquisition +40,000 – 80,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 43,343,616 21.1% 36.3
31 Aug 2026 41,426,996 20.2% 24.3
14 Aug 2026 38,505,948 18.7% 27.1
31 Jul 2026 36,819,551 18.0% 20.1
15 Jul 2026 34,140,223 16.7% 20.8
30 Jun 2026 32,028,140 15.6% 12.6

Discussion

No comments yet — be the first to weigh in on SVRA.

Leave a comment

Scroll to Top